226 studies found for:    immune, niaid | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
Condition: Human Immunodeficiency Virus
Intervention:
22 Recruiting Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Condition: Influenza A Virus Infection
Interventions: Biological: High-titer anti-influenza plasma;   Biological: Low-titer (control) anti-influenza plasma
23 Recruiting Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
Condition: Latent Tuberculosis Infection
Intervention:
24 Recruiting Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers
Condition: Host Response to RSV A2 Infection
Intervention: Biological: RSV A2 Study Agent
25 Recruiting Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Condition: APECED
Intervention:
26 Recruiting CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
Condition: HIV, Inflammation
Interventions: Drug: Assess Safety;   Drug: Effect of drug on viral load;   Drug: Effect of drug on T-cell count;   Drug: Effect of drug on inflammatory biomarkers
27 Recruiting Human Immunity Against Staphylococcus Aureus Skin Infection
Condition: Staphylococcus Aureus Skin Infection
Intervention: Other: Killed Bacteria
28 Recruiting Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Condition: Chronic Granulomatous Disease
Intervention:
29 Recruiting Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Conditions: Prevention of Zika Infection;   Zika-Specific Immune Response
Intervention: Biological: VRC-ZKADNA085-00-VP
30 Recruiting Studies of Disorders With Increased Susceptibility to Fungal Infections
Conditions: Primary Immune Deficiency;   Candida;   Autoimmune Polyendocrinopathy Candidiasis Ectodermal;   Chronic Mucocutaneous Candidiasis (CMC);   Fungal Infection
Intervention:
31 Recruiting Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Condition: Primary Immune Deficiency
Intervention:
32 Recruiting Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
Condition: Coccidioidomycosis
Intervention:
33 Recruiting High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Condition: X-Linked Chronic Granulomatious Disease
Interventions: Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
34 Recruiting Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
Condition: Chronic Granulomatous Disease
Interventions: Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
35 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Condition: Autoimmune Lymphproliferative Syndrome
Intervention:
36 Recruiting Parasitic Infections of the Gastrointestinal Tract
Conditions: Amebiasis;   Cryptosporidiosis;   Giardiasis;   Parasitic Disease;   Parasitic Intestinal Disease;   Gastrointestinal Helminth Infections
Intervention:
37 Recruiting Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Conditions: Anticytokine Autoantibody-Associated Diseases;   Disseminated Non-Tuberculous Mycobacteria;   Chronic Mucocutaneous Candidiasis;   Pulmonary Alveolar Proteinosis (PAP)
Intervention: Drug: Rituximab/Rituxan
38 Recruiting Influenza in People With Normal and Weakened Immune Systems
Condition: Influenza
Intervention:
39 Recruiting Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
Conditions: Healthy Volunteers;   Abnormal Phagocyte Function
Intervention:
40 Recruiting Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Condition: HIV
Intervention: Biological: Entyvio (Vedolizumab)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years